Ocular Therapeutix is a commercial-stage company that sells DEXTENZA and is developing AXPAXLI, an axitinib implant injected into the eye for wet AMD and diabetic retinopathy; AXPAXLI is not approved.
Ocular's case rests on AXPAXLI, an axitinib implant injected into the eye that blocks VEGF receptors for months. In the randomized SOL-1 Phase 3 trial, 65.9% of patients given one AXPAXLI injection maintained vision at week 52. That compared with 44.2% after one aflibercept 2 mg injection (p=0.0006). FDA's Type C minutes support an NDA on SOL-1, interim SOL-R safety data and confirmatory evidence. Ocular plans to submit in the fourth quarter; cash lasts into 2028, excluding full launch costs.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: The AXPAXLI NDA is submitted and accepted
Does Ocular submit the NDA on time, and does FDA accept it for review on SOL-1 data?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Ocular plans a fourth-quarter NDA for AXPAXLI in wet AMD based on SOL-1
AXPAXLI's Phase 3 superiority over aflibercept sets up an NDA bet on whether FDA accepts SOL-1 data via 505(b)(2) and SOL-R confirms the profile
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Eye diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
7 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.